STAT+: Pharmalittle: Some employers cut insurance coverage for weight loss drugs; U.S. urges ADHD pill makers to boost production
STAT
AUGUST 2, 2023
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. Besides the $26,500 annual price tag, treatment could cost U.S. About 1 million Alzheimer’s patients in the U.S. Medicare and Medicaid patients will make up 92% of the market for the drug, called Leqembi.
Let's personalize your content